Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

Breast Cancer Research

Volumn 13, Issue 2, 2011, Pages

  Hutcheson, Iain R ^a,b   Goddard, Lindy ^b   Barrow, Denise ^b   McClelland, Richard A ^b   Francies, Hayley E ^b   Knowlden, Janice M ^b   Nicholson, Robert I ^b   Gee, Julia M W ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR; FULVESTRANT; NEU DIFFERENTIATION FACTOR; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; HEREGULIN BETA1; RECEPTOR TYROSINE PROTEIN KINASE ERBB 4; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIGNAL PEPTIDE;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUREGULIN-1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 79961011383     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2848     Document Type: Article

References (58)

1. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 2003, 10:179-186. 10.1677/erc.0.0100179, 12790780.
2. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574. 10.1210/en.2003-0567, 12959972.
3. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004, 64:1522-1533. 10.1158/0008-5472.CAN-03-3326, 14973112.
4. Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer 2006, 13(Suppl 1):S77-S88. 10.1677/erc.1.01274, 17259561.
5. Gee JM, Stone A, McClelland RA, Hiscox SE, Hutcheson IR, Jordon NJ, Fiegl HM, Widschwendter M, Shaw VE, Barrow D, Nicholson RI. The dark side of antihormonal action in breast cancer. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and Their Potential as Targets 2009, 63-84. London: Springer, Hiscox S, Gee J, Nicholson RI.
6. Bates NP, Hurst HC. An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 1997, 15:473-481. 10.1038/sj.onc.1201368, 9242384.
7. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000, 19:490-497. 10.1038/sj.onc.1203416, 10698518.
8. Yarden RI, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl 2001, Suppl 36:232-246. 10.1002/jcb.1142, 11455588.
9. Wilson MA, Chrysogelos SA. Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. J Cell Biochem 2002, 85:601-614. 10.1002/jcb.10168, 11968000.
10. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003, 144:5105-5117. 10.1210/en.2003-0705, 12960029.
11. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS. ERBB2 regulation by estrogen receptor-Pax2 determines tamoxifen response. Nature 2008, 456:663-666. 10.1038/nature07483, 2920208, 19005469.
12. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044. 10.1210/en.2002-220620, 12586780.
13. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68:826-833. 10.1158/0008-5472.CAN-07-2707, 18245484.
14. Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I. The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 2003, 80(Suppl 1):S29-S35. 10.1023/A:1025467500433, 14535532.
15. Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, Gee JM. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord 2007, 8:241-253. 10.1007/s11154-007-9033-5, 17486454.
16. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW. Relationship between EGF-R, c-ErbB2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993, 29A:1018-1023. 10.1016/S0959-8049(05)80215-1, 8098946.
17. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 1994, 29:117-125. 10.1007/BF00666187, 7912565.
18. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005, 12(Suppl 1):S99-S111. 10.1677/erc.1.01005, 16113104.
19. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005, 23:2469-2476. 10.1200/JCO.2005.01.172, 15753463.
20. Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F. Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 2009, 16:675-702. 10.1677/ERC-08-0208, 19525314.
21. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:1979-1987. 10.1158/1078-0432.CCR-09-1823, 20332324.
22. Revillion F, Pawlowski V, Lhotellier V, Louchez MM, Peyrat JP. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen. Anticancer Res 2003, 23:1455-1460.
23. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 2006, 66:7991-7998. 10.1158/0008-5472.CAN-05-4397, 16912174.
24. Hayes NV, Gullick WJ. The neuregulin family of genes and their multiple splice variants in breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:205-214. 10.1007/s10911-008-9078-4, 18415007.
25. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989, 86:9193-9197. 10.1073/pnas.86.23.9193, 298460, 2687875.
26. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R. Involvement of heregulin-β2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 1996, 56:3350-3358.
27. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de Cremoux P, Stenvang J, Lykkesfeldt AE. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009, 114:263-275. 10.1007/s10549-008-0011-8, 2764248, 18409071.
28. Ghayad SE, Vendrell JA, Larbi SB, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010, 126:545-562. 10.1002/ijc.24750, 19609946.
29. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of ErbB3 abrogates ErbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882. 10.1002/ijc.22423, 17266042.
30. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004, 6:R246-R251. 10.1186/bcr783, 400680, 15084248.
31. Folgiero V, Avetrani P, Bon G, Di Carlo SE, Fabi A, Nisticò C, Vici P, Melucci E, Buglioni S, Perracchio L, Sperduti I, Rosanò L, Sacchi A, Mottolese M, Falcioni R. Induction of ErbB-3 expression by α6β4 integrin contributes to tamoxifen resistance in ER 1-negative breast carcinomas. PLoS One 2008, 3:e1592. 10.1371/journal.pone.0001592, 2220038, 18270579.
32. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. Wwox and Ap2γ expression levels predict tamoxifen response. Clin Cancer Res 2007, 13:6115-6121. 10.1158/1078-0432.CCR-07-1282, 17947476.
33. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001, 61:6500-6510.
34. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87:746-750. 10.1093/jnci/87.10.746, 7563152.
35. Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, Katzenellenbogen BS. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci 1995, 761:148-163. 10.1111/j.1749-6632.1995.tb31376.x, 7625718.
36. McClelland RA, Manning DL, Gee JM, Anderson E, Clarke R, Howell A, Dowsett M, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat 1996, 41:31-41. 10.1007/BF01807034, 8932874.
37. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 10.1073/pnas.1537685100, 166416, 12853564.
38. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005, 65:1384-1393. 10.1158/0008-5472.CAN-04-3150, 15735025.
39. Määttä JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2006, 17:67-79. 1345647, 16251361.
40. Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 1999, 59:5315-5322.
41. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297. 10.1002/path.1370, 12845624.
42. Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, Ellis IO. C-ErbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 1996, 74:229-233. 10.1038/bjc.1996.342, 2074568, 8688326.
43. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003, 106:758-765. 10.1002/ijc.11273, 12866037.
44. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC. Expression of the ERBB3 gene product in breast cancer. Br J Cancer 1992, 66:1116-1121. 10.1038/bjc.1992.420, 1978009, 1333787.
45. Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol 2010, 74:73-78. 10.1016/j.critrevonc.2009.04.011, 19481955.
46. Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg 2010, 251:1107-1116. 10.1097/SLA.0b013e3181dbb77e, 20485140.
47. Lee Y, Cho S, Seo JH, Shin BK, Kim HK, Kim I, Kim A. Correlated expression of ErbB-3 with hormone receptor expression and favourable clinical outcome in invasive ductal carcinomas of the breast. Am J Clin Pathol 2007, 128:1041-1049. 10.1309/GA5VRFQFY5D0MVKD, 18024331.
48. Knowlden JM, Gee JM, Seery LT, Farrow L, Gullick WJ, Ellis IO, Blamey RW, Robertson JF, Nicholson RI. c-erbB-3 and c-erbB-4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998, 17:1949-1957. 10.1038/sj.onc.1202107, 9788438.
49. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas: c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196:17-25. 10.1002/path.1003, 11748637.
50. Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RC, Angus B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol 2003, 56:300-304. 10.1136/jcp.56.4.300, 1769922, 12663644.
51. Offterdinger M, Schöfer C, Weipoltshammer K, Grunt TW. c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 2002, 157:929-939. 10.1083/jcb.200109033, 2174048, 12045181.
52. Ni CY, Murphy MP, Golde TE, Carpenter G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001, 294:2179-81. 10.1126/science.1065412, 11679632.
53. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001, 21:4265-4275. 10.1128/MCB.21.13.4265-4275.2001, 87087, 11390655.
54. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res 2006, 66:6412-6420. 10.1158/0008-5472.CAN-05-2368, 16778220.
55. Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, Ben-Baruch N, Leitner O, Ratzkin BJ, Bacus SS, Yarden Y. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem 1996, 271:7620-7629. 10.1074/jbc.271.13.7620, 8631797.
56. Cohen BD, Green JM, Foy L, Fell HP. HER4-mediated biological and biochemical properties in NIH 3T3 cells: evidence for HER1-HER4 heterodimers. J Biol Chem 1996, 271:4813-4818. 10.1074/jbc.271.9.4813, 8617750.
57. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999, 18:2607-2615. 10.1038/sj.onc.1202612, 10353604.
58. Sonne-Hansen K, Norrie IC, Emdal KB, Benjaminsen RV, Frogne T, Christiansen IJ, Kirkegaard T, Lykkesfeldt AE. Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance. Breast Cancer Res Treat 2010, 121:601-613. 10.1007/s10549-009-0506-y, 19697122.